Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Adams D, et al. Among authors: sekijima y. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Free article. Clinical Trial.
The diflunisal trial: update on study drug tolerance and disease progression.
Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, Ando Y, Ikeda SI, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Suhr OB; Familial Amyloidosis Consortium. Berk JL, et al. Among authors: sekijima y. Amyloid. 2011 Jun;18 Suppl 1:196-7. doi: 10.3109/13506129.2011.574354073. Amyloid. 2011. PMID: 21838485 No abstract available.
The Diflunisal Trial: study accrual and drug tolerance.
Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, Ando Y, Ikeda S, Gorevic P, Merlini G, Kelly JW, Skinner M, Bisbee AB, Dyck PJ, Obici L; Familial Amyloidosis Consortium. Berk JL, et al. Among authors: sekijima y. Amyloid. 2012 Jun;19 Suppl 1:37-8. doi: 10.3109/13506129.2012.678509. Epub 2012 May 2. Amyloid. 2012. PMID: 22551208 Clinical Trial.
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ; Diflunisal Trial Consortium. Berk JL, et al. Among authors: sekijima y. JAMA. 2013 Dec 25;310(24):2658-67. doi: 10.1001/jama.2013.283815. JAMA. 2013. PMID: 24368466 Free PMC article. Clinical Trial.
Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S. Ando Y, et al. Among authors: sekijima y. J Neurol Sci. 2016 Mar 15;362:266-71. doi: 10.1016/j.jns.2016.01.046. Epub 2016 Jan 22. J Neurol Sci. 2016. PMID: 26944161 Clinical Trial.
321 results